Comparing acute toxicity of first- and second-generation antipsychotic drugs: A 10-year, retrospective cohort study

Journal of Clinical Psychiatry

Volumn 70, Issue 1, 2009, Pages 122-129

  Ciranni, Michael A ^a   Kearney, Thomas E ^b   Olson, Kent R ^b  

^a NEW YORK UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BENPERIDOL; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; MELPERONE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PROTHIPENDYL; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; COHORT ANALYSIS; COMA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DYSTONIA; FEMALE; FEVER; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUROLEPTIC MALIGNANT SYNDROME; OUTCOME ASSESSMENT; POISON CENTER; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; RESPIRATION DEPRESSION; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; RIGIDITY; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; CAUSE OF DEATH; COHORT STUDIES; COMA; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FOLLOW-UP STUDIES; HUMANS; HYPOTENSION; LONG QT SYNDROME; NEUROLEPTIC MALIGNANT SYNDROME; ODDS RATIO; OVERDOSE; POISON CONTROL CENTERS; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; SURVIVAL ANALYSIS;

EID: 60349091539     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04315     Document Type: Article

References (36)

1. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep;353(12):1209-1223
2. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996;57(suppl 11):53-60
3. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2000;60:553-564
4. Brown CS, Markowitz JS, Moore TR, et al. Atypical antipsychotics, pt 2: adverse effects, drug interactions, and cost. Ann Pharmacother 1999;33:210-217
5. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999;60(suppl 10):5-14
6. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl) 1996;124(1-2):2-34
7. Jones PB, Barnes TRE, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63(10):1079-1087
8. Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. J Toxicol Clin Toxicol 2001;39(1):1-14
9. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696
10. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotics: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62:19-28
11. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59(11):1021-1026
12. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial. Arch Gen Psychiatry 2003;60:82-91
13. Lai MW, Klein-Schwartz W, Rodgers GC, et al. 2005 Annual Report of the American Association of Poison Control Centers' national poisoning and exposure database. Clin Toxicol (Phila) 2006;44:803-932
14. Watson WA, Litovitz TL, Belson MG, et al. The Toxic Exposure Surveillance System (TESS): risk assessment and real-time toxicovigilance across United States poison centers. Toxicol Appl Pharmacol 2005;207(2):604-610
15. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is "normal." J Cardiovasc Electrophysiol 2006;17:333-336
16. Bazett HC. An analysis of time relations of electrocardiograms. Heart 1920;7:353-367
17. Josephson ME. Clinical Cardiac Electrophysiology: Techniques and Interpretations. 3rd ed. Philadelphia, Pa: Lippincott and Wilkins; 2002
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
19. Dunkley EJC, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Q J Med 2003;96:635-642
20. Owens DG. Adverse effects of antipsychotic agents: do newer agents offer advantages? Drugs 1996;51(6):895-930
21. Levinson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142(10):1137-1145
22. Hasan S, Buckley P. Novel antipsychotics and the neuroleptics malignant syndrome: a review and critique. Am J Psychiatry 1998;155:1113-1116
23. Reilly JG, Ayis SA, Ferrier IN, et al. Thioridazine and sudden unexplained death in psychiatric inpatients. Br J Psychiatry 2002;180:1515-1522
24. Stollberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 2005;20(5):243-251
25. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24(1):62-69
26. Brown K, Levy H, Brenner C, et al. Overdose of Risperidone. Ann Emerg Med 1993;22:1908-1910
27. Elian AA. Fatal overdose of olanzapine. Forensic Sci Int 1998;91:231-235
28. Reith D, Monteleone PR, Whyte IM, et al. Features and toxicokinetics of clozapine in overdose. Ther Drug Monit 1998;20:92-97
29. Scahill L, Blair J, Leckman JF, et al. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone. J Psychopharmacol 2005;19(2):205-206
30. LeBlaye I, Donatini B, Hall M, et al. Acute overdosage with clozapine: a review of the available clinical experience. Pharmaceutical Med 1992;6:169-178
31. Hollister LE, Kosek JC. Sudden death during treatment with phenothiazine derivatives. JAMA 1965;192:1035-1038
32. Ray WA, Meredeith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58:1161-1167
33. Steffens DC, Krishnan KRR, Helms IM. Are SSRIs better than TCAs? comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 1998;6(1):10-18
34. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998;7(suppl 1):11-17
35. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998;59(suppl 15):42-48
36. Stoner SC, Marken PA, Watson WA, et al. Antidepressant overdoses and resultant emergency department services: the impact of SSRIs. Psychopharmacol Bull 1997;33:667-670